Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial

Calvin J. Cohen, Daniel S. Berger, Gary Blick, Howard A. Grossman, Dushyantha T. Jayaweera, Peter Shalit, Melanie Thompson, Monika Peeters, Marie Pierre De Béthune, Ellen Voorspoels, Rebecca Mack, Brian Woodfali

Research output: Contribution to journalArticle

20 Scopus citations

Abstract

Forty-eight-week results from a randomized, multicentre, part-blinded, phase IIb clinical trial assessing the efficacy and safety of 400 and 800 mg etravirine twice daily (phase IIb formulation) and optimized background regimen versus standard- of-care regimen are presented. Both etravirine doses demonstrated sustained virological suppression at 48 weeks and a favourable tolerability profile. Etravirine demonstrated higher efficacy than control, irrespective of the number of detectable nonnucleoside reverse transcriptase inhibitor-resistance-associated mutations at baseline or active background antiretrovirals.

Original languageEnglish (US)
Pages (from-to)423-426
Number of pages4
JournalAIDS
Volume23
Issue number3
DOIs
StatePublished - Jan 28 2009

    Fingerprint

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Infectious Diseases

Cite this

Cohen, C. J., Berger, D. S., Blick, G., Grossman, H. A., Jayaweera, D. T., Shalit, P., Thompson, M., Peeters, M., De Béthune, M. P., Voorspoels, E., Mack, R., & Woodfali, B. (2009). Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial. AIDS, 23(3), 423-426. https://doi.org/10.1097/QAD.0b013e32831c5040